Abstract | Aberrant chromosomal architecture, ranging from small insertions or deletions to large chromosomal alterations, is one of the most common characteristics of cancer genomes. Chromosomal instability (CIN) underpins much of the intratumoural heterogeneity observed in cancers and drives phenotypic adaptation during tumour evolution. Thus, an urgent need exists to increase our efforts to target CIN as if it were a molecular entity. Indeed, CIN accelerates the development of anticancer drug resistance, often leading to treatment failure and disease recurrence, which limit the effectiveness of most current therapies. Identifying novel strategies to modulate CIN and to exploit the fitness cost associated with aneuploidy in cancer is, therefore, of paramount importance for the successful treatment of cancer. Modern sequencing and analytical methods greatly facilitate the identification and cataloguing of somatic copy-number alterations and offer new possibilities to better exploit the dynamic process of CIN. In this Review, we describe the principles governing CIN propagation in cancer and how CIN might influence sensitivity to immune-checkpoint inhibition, and survey the vulnerabilities associated with CIN that offer potential therapeutic opportunities.
Aneuploidy, defined as the presence of an abnormal number of chromosomes, is one of the most striking and widespread features of human cancers. The vast majority of tumours also display various types of somatic copy-number alterations (SCNAs), including segmental aneuploidies, focal events, and/or whole-chromosome aneuploidies. Considering only the most frequent cancers, approximately 60% of non-small-cell lung cancers (NSCLCs), 60-80% of breast tumours, 70% of colorectal tumours and 30% of prostate tumours deviate from a diploid karyotype [1] [2] [3] [4] [5] [6] . Tumours that do not harbour gross aneuploidy often display hypermutation owing to mismatch-repair deficiencies or mutations in DNA polymerase-ε and/or DNA polymerase-δ catalytic subunit 1, which might reflect the maximum amount of genetic instability that cancer cells can handle without inducing lethality 7 . Chromosomal instability (CIN) refers to the ongoing acquisition of genomic alterations that can involve either a gain or loss of whole chromosomes (W-CIN) or structural aberrations (S-CIN), which range from point mutations to small-scale genomic alterations and gross chromosomal rearrangements. However, aneuploidy (an aberrant genomic state) and CIN (the property of displaying a high rate of genomic changes) might differ in their prognostic value, a distinction that warrants careful investigation. In this Review, we discuss the implications of CIN for tumour evolution, provide an overview of the causes of CIN in cancer, with an emphasis on the mechanisms enabling CIN propagation, and describe potential strategies to target CIN therapeutically in patients with cancer.
Chromosomal instability: opening Pandora's box Mitotic causes of chromosomal instability. Malignant cells with CIN rapidly acquire SCNAs during proliferation, creating intratumour genetic heterogeneity within the population. A myriad of specific defects often leads to aberrant segregation of chromosomes during cell division. These mechanisms and their causative role in cancer have been reviewed in detail previously 8, 9 . These defects include those that directly impinge on the chromosome segregation machinery, such as altered microtubule spindle dynamics, mechanisms required to correct erroneous microtubule-kinetochore attachments, and defects affecting the mitotic checkpoint or sister-chromatid cohesion [8] [9] [10] [11] [12] [13] [14] . Supernumerary centrosomes are frequently observed in cancer cells and threaten the stability of the genome by increasing the probability of merotelic attachments, a type of microtubule-kinetochore attachment defect that enables cell division to proceed without activation of the mitotic checkpoint 12, 15 . The failure to cluster extra centrosomes into two poles then leads to a multipolar , can directly impair the fidelity of chromosome segregation processes during the ensuing rounds of division owing to the presence of extra centrosomes 15, 20 (FIG. 1) . Tetraploidization is not only linked with the development of cancer but is also part of the developmental programme of several differentiated cell types, such as hepatocytes, megakaryocytes, and placental trophoblasts, which can become highly polyploid. In addition, tetraploidy can be found in non malignant ageing tissues (such as hepatocytes and endothelial cells) and in cells exposed to various stressors 21, 22 . Genome doubling is a common feature of human cancer cells and has been reported to occur in >40% of lung, head-and-neck, breast, bladder, colorectal, oesophageal, and ovarian cancers 2, 23, 24 . Of note, sequencing-based studies can enable the identification of tumours that have undergone whole-genome doubling (WGD) during development, even if the genome is no longer tetraploid at diagnosis owing to chromosomal losses. This observation explains the possible discrepancy between the findings of different cytometry-based studies, in which estimates of WGD are based on cells having an exactly tetraploid genome. For example, computational genomics-based approaches suggest that >50% of breast cancer biopsy samples contained cells that had undergone WGD 2 , whereas a large-scale cytometry-based study revealed tetraploid cells in only 32% of tumours 25 . The results of genomic studies suggest that genome doubling is an early event in the evolution of several cancers that precedes the acquisition of additional SCNAs and subclonal expansion 23, 24, 26, 27 . Correspondingly, tetraploid cells have been detected in pre-malignant lesions in patients with oesophageal, cervical, breast or head-and-neck cancers 25, [28] [29] [30] . Genome doubling could, therefore, be the CIN-initiating event in a substantial proportion of human cancers.
Structural defects trigger chromosomal instability.
Aneuploid tumours almost invariably contain both numerical and structural chromosomal aberrations.
Pre-mitotic defects, such as replication stress, can generate chromosome fusions that result in dicentric chromosomes, including those created by telomere fusion, and acentric chromosome fragments, both of which might be randomly distributed in daughter cells 31 . DNA bridges between dicentric chromosomes can also physically prevent cell division and generate tetraploid cells, which are inherently prone to CIN [32] [33] [34] [35] . Under-replicated regions might also prevent the physical separation of chromosomes during mitosis, leading to aneuploidy 36 . Consequently, numerical chromosomal aberrations can be symptomatic of DNA replication stress without underlying defects in the chromosome segregation machinery. Replication stress, therefore, provides an alternative route through which complex karyotypes can develop: through the uneven distribution of damaged genetic material during division.
W-CIN, S-CIN and nuclear envelope defects. The findings of several studies indicate that aberrantly segregated chromosomes are prone to the accumulation of mutations and further structural defects. Errors during mitosis can, for example, result in lagging chromosomes during the partitioning of DNA into daughter cells, which might become trapped during cell division or become isolated and form micronuclei. Both situations create a context in which DNA might sustain extensive damage and chromosomal rearrangements, including chromothripsis 37, 38 . Interestingly, micronuclei and DNA bridges both display signs of nuclear envelope disruption, such as defects in nuclear lamin organization, suggesting loose compartmentalization within the cytoplasm, which potentially exposes DNA to reactive oxygen species and cytoplasmic enzymes. In micronuclei, aberrant DNA replication is correlated with collapse of the nuclear envelope in addition to the massive accumulation of DNA damage and chromothripsis [37] [38] [39] . Importantly these observations are not limited to in vitro analyses, as micronuclei with a disrupted nuclear envelope and accumulation of DNA damage can be easily found in paraffin-embedded NSCLC specimens 39 . The integrity of the nuclear envelope is also lost when dicentric chromosomes create ultrafine DNA bridges, which can also lead to chromothripsis and hypermutation of localized chromatin regions (kataegis) 40 . Loss of the nuclear envelope exposes ultrafine DNA bridges to a cytoplasmic nuclease, creating single-stranded DNA, which is the substrate of mutagenic DNA dC→dU-editing enzyme APOBEC3G (APOBEC3G). This event could explain the APOBEC mutational signature that is often found near chromosomal rearrangement breakpoints 40, 41 . The physical, yet often transient, isolation of DNA during CIN might contribute to the highly localized nature of APOBEC-driven mutations in cancer as well as the appearance of such mutations following the onset of CIN during tumour evolution [42] [43] [44] . Interestingly, cell migration through tight spaces and exposure to excessive cytoskeletal forces can both exert pressure on the nucleus, leading to rupture of the nuclear envelope, chromatin extrusion, DNA damage [45] [46] [47] , and karyotypic abnormalities 47 . The process of
Key points
• Chromosomal instability (CIN) drives intratumoural heterogeneity, resulting in the temporal and spatial diversification of tumour subclones • CIN enables cancer cells to rapidly explore complex genetic makeups by potentially causing the simultaneous acquisition of whole-chromosome or segmental aneuploidy, structural chromosomal aberrations, and the acquisition of mutations • CIN accelerates phenotypic adaptation under selective pressures encountered during tumour evolution and therapy, leading to a poor clinical outcome • Paradoxically, high levels of CIN are tumour suppressive owing to the frequent generation of unviable karyotypes, while CIN tolerance and attenuation mechanisms allow an optimal equilibrium to be reached, leading to sustainable CIN propagation • A deeper understanding of the vulnerabilities associated with CIN and the development of clinically applicable biomarkers are needed both for patient stratification and to leverage new therapeutic opportunities epithelial-to-mesenchymal transition (EMT) induced by TGFβ, which is often associated with metastasis, has also been linked with CIN and defects in the nuclear envelope 48 . Physical constraints and paracrine effects associated with the dissemination of malignant cells therefore provide additional routes to genomic instability.
Cancer-cell extrinsic causes of CIN. Additional cellextrinsic or non-genetic causes of CIN have also been proposed, in addition to mechanical forces exerted upon the nucleus and paracrine induction of EMT, as described earlier. Glucose deprivation, hypoxia, or acidification of the extracellular milieu, which mimic the properties of the tumour microenvironment, can induce genomic instability and aneuploidy 49, 50 . Entosis, the process of engulfment by another cell, causes tetraploidy and CIN by blocking division of the host cell and has been reported to be present at a low frequency in human tumour specimens 51, 52 . In summary, chromosome segregation errors can potentially trigger a chain of events that result in extensive numerical and structural chromosomal aberrations and cause the acquisition of mutations. Indeed, numerous examples exist demonstrating that aneuploidy itself can be a trigger of further CIN and chromosomal rearrangements [53] [54] [55] ; aneuploid and tetraploid cells evolve Figure 1 | Merotely, tetraploidy, and chromosomal instability attenuation. a | Several types of mitotic defects can lead to aberrant chromosome segregation. Those illustrated herein are merotelic attachments, whereby one of the sister chromatids (magenta) is attached to opposite poles. These errors are not detected by the mitotic checkpoint, hence, mitosis proceeds without delay, resulting in a lagging chromosome that can undergo aberrant segregation, leading to aneuploid daughter cells. Severe defects (excessive chromosomal instability (CIN)) generate a high frequency of daughter cells with an unviable aneuploid karyotype that deviates greatly from a 2n diploid content (2n ± x) owing to the loss or gain of too many chromosomes (dark red daughter cells). b | Infrequent segregation errors involving fewer chromosomes likely generate viable progeny (orange daughter cells), whose proliferation will then depend on the various mechanisms of aneuploidy tolerance. The frequency of segregation errors can be attenuated by acquiring secondary alterations that improve mitotic fidelity. APC/C (anaphase-promoting complex; also known as the cyclosome) dysfunction is one mechanism that leads to CIN attenuation by delaying mitosis, thus providing more time for endogenous mechanisms to correct attachment errors. c | Supernumerary centrosomes in tetraploid cells (4n) frequently generate multipolar spindles and merotelic attachments. Failure to cluster these extra centrosomes into two poles will lead to a multipolar division (resulting in 3 or 4 daughter cells, as shown), often with severe and random chromosome losses (4n -x). The presence of extra centrosomes also greatly increases the risk of merotely. d | Tetraploid cells avoid multipolar divisions through centrosome clustering, which requires kinesin-like protein KIFC1. Tetraploid cells are believed to be more tolerant of segregation errors than diploid cells because such errors have a milder effect on overall protein stoichiometry. Delaying mitotic progression provides more time to achieve centrosome clustering and reduces the frequency of segregation errors, thus improving tetraploid cell fitness and the propagation of a sustainable rate of CIN (yellow daughter cells).
to gradually accumulate further whole-chromosome and segmental aberrations with time 20, 24, 34, [54] [55] [56] . Consequently, even infrequent aberrant segregation events in cancer cells can induce a dramatic increase in cell fitness (referring to the potential to replicate without necessarily immediately triggering a hyperproliferative state) by causing profound copy-number alterations (CNAs) and the acquisition of point mutations.
CIN accelerates evolution and therapy resistance CIN provides tumour cells with an efficient means of responding to various selective pressures, as exemplified by experimental data from various preclinical models [56] [57] [58] [59] . Rare clones within karyotypically hetero geneous populations will often outcompete other cells only when exposed to selective pressures 57 ; tetraploidization in particular facilitates the rapid acquisition of CNAs and mutations in response to stressful conditions, leading to increased cell fitness 56, 58 . CIN and tetraploidization also confer multidrug resistance, including resistance to some of the most commonly used chemo therapeutic agents, by creating greater levels of genetic diversity and thus promoting the emergence of drug-resistant clones 60, 61 . Oncogene addiction, the basic principle behind the effectiveness of molecularly targeted therapies 62 , can also be circumvented by ongoing CIN. Elegant experiments using inducible mouse models have shown that CIN (driven by overexpression of mitotic spindle assembly checkpoint protein MAD2A) in combination with expression of the KRAS G12D or HER2 oncogenes, can consistently contribute to bypass oncogene addiction upon oncogene withdrawal, thereby facilitating tumour relapse and persistance 63, 64 . Thus, CIN offers a mechanism of escape following treatment with targeted therapies and suggests that the loss of oncogenic driver mutations following a copy-number-altering event would not be as deleterious in cancer cells with ongoing CIN. This hypothesis describes a conceivable scenario given that ongoing CIN contributes to mutational hetero geneity by enabling the loss of chromosomal regions previously harbouring clonal oncogenic mutations, as observed in NSCLC 65 and breast cancer 26 . CIN is also an important driver of parallel tumour evolution. In NSCLC, focal amplification of driver genes takes place in different alleles across different tumour subclones, a process referred to as mirrored subclonal allelic imbalance, which is indicative of ongoing CIN 65 .
Comparisons of SCNAs in circulating tumour cells (CTCs) and metastatic tumours have also revealed convergence towards common SCNAs in patients with various types of cancer 66 . Of note, neither of these studies 65,66 revealed convergence at the mutational level, suggesting that CIN enables more rapid selection of driver events than other mutagenic processes, in some cancers. Convergence at the copy-number level, involving loss of heterozygosity or oncogene amplification, has been reported in patients with high-grade ovarian cancer 67 . The emergence of resistance during therapy can also proceed through parallel convergence. For example, resistance to ERK inhibition has been shown to occur through parallel amplification of BRAF in divergent clones, while the development of acquired resistance to a PI3Kα inhibitor arose through independent inactivating events affecting the remaining PTEN allele across separate metastatic lesions in a patient with breast cancer 68, 69 . Thus, CIN enables cells to enter several different evolutionary trajectories and adapt to the selective pressures created by therapy, a process that underlies treatment failure. Radiation therapy 70 , as well as many of the most commonly used chemotherapeutic drugs have been shown to induce CIN in vitro. Induction of CIN in cell lines has been demonstrated for several classes of anticancer compounds targeting microtubules (taxanes) and DNA-damage-response pathways (poly [ADP-ribose] polymerase inhibitors and topoisomerase inhibitors), as well as for DNA intercalating agents (cisplatin) or nucleoside analogues (gemcitabine) 71, 72 . Notably, under certain conditions, induction of CIN was exacerbated when using drug combinations below their respective half-maximal inhibitory concentration (IC 50 ) values 71 . The effectiveness of several drugs that are currently considered the standard-of-care treatments for various malignancies could be linked to their common effect of driving the development of excessive levels of genomic instability in cancer cells. On the basis of this interpretation, what would make cancer cells exquisitely sensitive to several of these compounds is not the ability to proliferate faster than nonmalignant cells but rather the loss of regulation by various cell-cycle checkpoints, resulting in the acquisition of additional SCNAs beyond a threshold that would be compatible with cell survival.
Mechanisms enabling CIN propagation
Aneuploidy tolerance. The ability to cope with genetic imbalances is a fundamental difference between malignant and nonmalignant cells. The deleterious effects of aneuploidy on cellular proliferation have been documented for numerous nonmalignant cell types 73 . For example, in the haematopoietic compartment, aneuploid cells are outcompeted owing to slower proliferation than many of their diploid counterparts 74 . Aneuploidy also impairs organismal development and is the main cause of spontaneous abortions in humans, with most constitutive aneuploidies having an embryonic lethal effect -trisomy of chromosome 21 (resulting in Down syndrome) being a rare exception 75 . Mechanistically, aneuploidy has profound consequences for gene dosage by causing imbalances in the expression of hundreds to thousands of genes residing on the extra chromosome(s) 76 . These imbalances result in a number of aneuploidy-associated stressors that impair overall cellular fitness by causing metabolic changes that affect the protein turnover machinery [77] [78] [79] . Chromosome gains seem to be particularly detrimental to cellular proliferation, and tumours are more likely to harbour chromosome losses than gains 54 . Thus, aneuploidy alone seems to be insufficient for the transformation of nonmalignant cells, and in fact, aneuploid cells are largely under negative selection pressure 54, 74 . These observations raise an important question: how to reconcile this observation with the often-reported high proliferation rate of aneuploid cancer cells. As discussed in the following paragraphs, mechanisms of aneuploidy tolerance that are associated with cellular transformation are thought to enable the propagation of CIN. In addition, tumour cells might not be as hyperproliferative in vivo as in vitro measurements would suggest. The proliferation rates of primary human tumours, which are based on radiographic measurements or derived from tumour biomarker levels, suggest that doubling times range from 30 days to several months (as reviewed extensively elsewhere 80 ). These measurements reflect a combination of cellular proliferation and other factors acting upon the fitness of cancer cells, such as immuno-editing, which might mask the rate of proliferation as determined purely by the intrinsic characteristics of the cells. Estimations of potential doubling time derived from in vivo measurements of 5-bromodeoxyuridine (BrdU) incorporation also suggest relatively slow doubling times compared with those of most cell lines in vitro, from 1-2 days in head-and-neck cancer 81, 82 , 4.5 days in colorectal cancer (CRC) 83 , and 12.5-28 days in breast cancer 84, 85 . Intravital imaging of tumours in immunocompromised mice also shows that cancer cell lines proliferate more slowly in vivo than in cell culture 86 . The ability of cancer cells to proliferate despite aneuploidy, even at a slow rate, might be a crucial determinant of the physiological relevance of CIN to tumour evolution.
Deciphering the factors that might enable cancer cells to tolerate aneuploidy then becomes important. Genetic alterations that improve protein turnover, and hence alleviate proteotoxic stress, have been reported to improve the fitness of aneuploid cells 87, 88 . TP53 disruption has been proposed as an important mechanism enabling the propagation of CIN, both in vitro and in mouse models. For example, mutations in TP53 and in APC (which encodes adenomatous polyposis coli (APC)) are strongly associated with CIN-positive CRCs 20, 31, [89] [90] [91] . The findings of studies published in the past year suggest that wild-type p53 does not always arrest cells following aberrant chromosome segregation, and some aneu ploidies can be propagated in p53-proficient cells 92, 93 . One hypothesis suggests that p53 does not detect whole-chromosome aneuploidies per se but that certain forms of aneuploidy (involving specific chromosomes or a combination thereof) generate a level of stress that is sufficient to induce p53 stabilization 92 . However, the propagation of structural aberrations might be exquisitely dependent on p53 disruption and linked with the acquisition of complex karyotypes 92, 93 . p53 stabilization following chromosome mis-segregation has been linked with DNA damage resulting from the entrapment of chromosomes during cytokinesis or from aberrant DNA replication and subsequent genomic alterations occurring within micronuclei 94 . The requirement for disruption of the p53 pathway, thus enabling propagation of CIN, might therefore be intimately linked with the co-occurrence of DNA damage at sites of chromosomal rearrangements that link numerical and structural aneuploidies.
Classical DNA-damage-response signalling alone cannot completely explain CIN-induced p53 stabilization, and under certain experimental conditions, stabilization occurs without p53 phosphorylation at sites associated with DNA damage; cell-cycle arrest also cannot be reverted using inhibitors of the serine-protein kinase ATM, another protein involved in DNA-damageresponse signalling 95 . Recently, caspase 2 was identified as an upstream regulator of p53 following chromosome mis-segregation 96 . Caspase 2 was found to cleave the E3 ubiquitin-protein ligase MDM2 in response to aberrant chromosome segregation, which is known to disrupt the ability of MDM2 to ubiquitylate p53 and thus promotes the proteasomal degradation of p53 (REF. 97 ). In CRC cell lines, maintenance of stable levels of caspase 2 activation was found to require B-cell chronic lymphocytic leukaemia (CLL)/lymphoma 9-like protein (BCL9L), which acts as a β-catenin cofactor for transcription of caspase 2. Mutational inactivation of BCL9L and caspase 2 downregulation have both been shown to confer tolerance of CIN 96 . Importantly, reduced caspase 2 levels also improved CIN tolerance in p53-deficient cells by impairing the generation of the pro-apoptotic product membrane-targeted BH3-interacting domain death agonist (tBID). Why caspase 2 becomes active after aberrant chromosomal segregation remains unclear. In summary, several signalling pathways converge on p53 and on the apoptotic machinery to control CIN tolerance in cancer cells. Activation of these pathways is most likely determined by the ability of cells to cope with global transcriptional and metabolic changes and the effects of the ongoing genomic rearrangements.
Tolerance of genome doubling. Tetraploid cells (that have undergone WGD) seem to be inherently more tolerant of the gain or loss of whole chromosomes, possibly owing to the effects on gene expression being less dramatic than when similar events occur in a diploid cell 24, 98 . The greater ability of tetraploid cells to tolerate the negative effects of the protein imbalances associated with aneuploidy, and their propensity to develop CIN owing to the presence of extra centrosomes, might explain why genome doubling is such a common precursor of CIN in the early stages of tumour development 23, 24, 27 (FIG. 1) .
However, the propagation of tetraploid cells immediately following the failure of cell division is limited, at least in part, by p53-mediated cell-cycle arrest at the G1 phase 99 , which might explain why TP53 mutations are more frequent in tetraploid tumours and why they tend to occur prior to genome doubling 100 . Activation of the Hippo signalling pathway, which regulates cell proliferation and apoptosis in response to an increase in centro somes and microtubule nucleation has been shown to contribute to p53 stabilization 101 . However, disruption of TP53 is not an obligatory step for the expansion of tetraploid cells, and several mechanisms have been described that enable p53 activation to be bypassed. Growth-factor signalling, for example, promotes the proliferation of tetraploid cells despite engagement of the p53-p21 axis 101 . This promotion of growth-factor signalling might be achieved in cancer through activating mutations in PIK3CA (encoding the p110α catalytic subunit of PI3K), which have been shown to confer tolerance to genome doubling 102 . In breast cancer, PIK3CA
H1047R mutations are predominantly clonal and occur before genome doubling 102 , with a similar association observed in samples from patients with colorectal adenocarcinoma (PIK3CA mutation) 27 or lung squamous cell carcinoma (amplification of chromosome 3q, which harbours the PIK3CA locus) 65 . Finally, overexpression of D-type cyclins, which link mitogenic signalling with cell-cycle progression 103 , enables the circumvention of G1 arrest following genome doubling by sequestering of p21 resulting from p53 transcriptional activation, thus preventing the growth-inhibitory effects of p21 (REFS 104, 105) . The upregulation of D-type cyclin levels could be an important mechanism by which PI3K-AKT and ERK signalling can contribute to bypass stabilization of p53 (REF. 106 ). 107 proposed that genomic instability might contribute to tumour development only if it does not exceed a certain threshold; beyond this threshold, genomic instability is likely to generate cells with unviable karyotypes. This principle can also be observed in bacterial genetics and virology, in which an excessive mutator phenotype has catastrophic consequences for population fitness 107 . This concept is supported by the observation that a high burden of SCNAs and greater levels of intratumour hetero geneity before treatment are both associated with improved overall survival outcomes, while tumours with intermediate levels of tumour heterogeneity are associated with a poor clinical outcome [108] [109] [110] . Accordingly, CIN can have either oncogenic or tumour-suppressive effects in mouse models according to the level of instability, which is affected by both the genetic context and the tissue 111, 112 . An increased rate of aberrant chromosome segregation increases the level of cell death observed in various cancer cell lines and also reduces their tumorigenic potential 113, 114 . In addition, the efficacy of some cancer treatments that induce CIN, such as paclitaxel and radiation therapy, is improved in cells with a higher basal rate of CIN 70, 113, 115 . The requirement to reach an equilibrium state of low CIN might explain the scarcity of mutations in genes whose experimental disruption induces considerable levels of CIN, as these would essentially be under negative selection. Analogous to Muller's ratchet principle 116 , which links the acquisition of mutations with species extinction, the accumulation of genomic alterations during tumour evolution might gradually increase the degree of CIN and lead to cancer cell death. Thus, alterations that limit the extent of CIN might be selected for during cancer progression. Tolerance of aneuploidy, although essential for the propagation of CIN, leaves cells vulnerable to extreme karyotypic alterations, raising a question as to whether CIN levels can be modulated during tumour development to mitigate against the effects of excessive instability.
CIN attenuation. Cahill and colleagues
Deleterious mutations in various subunits of the APC/C (anaphase-promoting complex; also known as the cyclosome) are reportedly selected for in cancer, with evidence showing that monoallelic inactivation of various APC/C subunits markedly reduces the accumulation of endogenous chromosome segregation errors in cancer cell lines 95 . APC/C dysfunction delayed the progression of mitosis by only 5-10 minutes, but this delay was sufficient to substantially improve the fidelity of chromosome segregation and the fitness of tetraploid cells and to reduce the frequency of merotelic attachment errors, which is considered a major cause of W-CIN 12 (FIG. 1) . Although cancer cells divide much less frequently in vivo than they do in vitro, data from intravital imaging studies suggest that the total duration of the mitotic phase (~1 h) itself is unchanged in vivo 86 , which is similar to that reported for various cell types in mouse embryos 117 . Pharmacological induction of extreme CIN in vitro rapidly selected for cells harbouring APC/C mutations or for reduced levels of APC/C activity, translating into a 10-minute delay in mitosis. The plasticity of mitotic duration, which merely affects the overall proliferation rate, offers an effective mechanism of attenuating many CINinducing defects 95 . Delaying mitotic progression also improves the fitness of tetraploid cells by facilitating centrosome clustering, which reduces the frequency of unviable multipolar divisions 16, 95, 118 . Thus, quantifying the presence of mitotic biomarkers, such as phosphory lated histone H3 or mitotic proteins recognized by anti-MPM-2 antibodies, might not be optimal methods of determining the proliferation index of fixed samples. Secondary alterations that improve cell fitness by reducing CIN might, therefore, be acquired during tumour evolution. Mild alterations in mitotic duration owing to genetic or epigenetic regulation of critical mitotic regulators might provide an effective mechanism of fine-tuning the level of CIN to optimize cancer-cell fitness.
A crucial determinant of CIN propagation, therefore, is the capacity of cancer cells to tolerate a given level of genetic instability, and disruption of this equilibrium is likely to impair cell fitness (FIG. 2) . For example, many cancer cell lines that have a stable karyotype will undergo aberrant chromosome segregation at non-negligible frequencies, yet these events are not tolerated, leading to cell death and the clearance of aneuploid cells 96 (FIG. 2) .
Indeed, APC-mutated organoids have a high frequency of segregation errors (and would appear as aneuploid by fluorescence in situ hybridization (FISH)), although the aneuploid progeny are not propagated efficiently, and the population does not become fully aneuploid unless TP53 is disrupted 91 . Reduced levels of CIN in evolved tetraploid cells can also be achieved by eliminating the extra centrosomes 15, 105 . Buffering of CIN is also a recurrent observation upon mathematical modelling of the evolutionary dynamics of genetically unstable populations, and cell fitness is generally improved when the degree of CIN is reduced [119] [120] [121] . Identifying additional mechanisms driving the adaptation to and tolerance of CIN might therefore reveal new strategies enabling CIN to be targeted therapeutically.
Immunosurveillance and CIN
A complex picture is emerging, whereby CIN could affect the recognition of cancer cells by the immune system in multiple and opposing ways. Successful immune evasion might be particularly crucial for the development of chromosomally unstable tumours owing to the likelihood that genomic alterations and stresses associated with aneuploidy might lead to an increase in tumour immunogenicity. An analysis of 5,255 tumour or nonmalignant tissue samples included in The Cancer Genome Atlas data set revealed that the presence of high-level segmental or whole-chromosome SCNAs in tumours is correlated with the reduced expression of several genes involved in adaptive immunity and/or related to cytotoxic CD8 + T cells and/or natural killer (NK) cells, suggesting a reduced level of immune-cell infiltration 122 . These observations have yet to be validated in vivo, although they do support the notion that the tumour microenvironment of highly aneuploid tumours is immunosuppressive, an observation that is further supported by a report indicating a lower frequency of neoantigen editing in CRC 122 . General features shared by cells with CIN might constitute an immunogenic trigger. This effect could in part be driven by endoplasmic reticulum (ER)-associated stress in polyploid cells, resulting in extracellular exposure of calreticulin and recognition by cytotoxic T cells and NK cells 123, 124 . Pharmacological induction of CIN using an MPS1 inhibitor induced a pro-inflammatory gene signature and increased cytokine secretion, cell-surface expression of NK-cellactivating ligands, and efficient clearance by NK92 cells in co-culture assays 93 . In syngeneic mouse xenograft models of ovarian cancer, combining an MPS1 inhibitor with antibodies against programmed cell death protein 1 (PD-1) potentiated tumour regression, although it is unclear whether immunogenicity was triggered by apoptotic cell death or by a specific feature of highly aneuploid cells caused by MPS1 inhibition 125 . Defects in nuclear envelope integrity, which occur in micronuclei and chromatin bridges or during cell migration, have been shown to enable recognition of DNA by cytosolic cyclic GMP-AMP synthase, a crucial sensor of double-stranded DNA that mediates type I interferon-dependent immune responses 126, 127 . This mechanism led to the activation of a pro-inflammatory programme downstream of the stimulator of interferon genes protein, which is known to promote anticancer T-cell responses 128 . The ER stress and transient exposure to cytosolic DNA associated with CIN are two mechanisms that might trigger a cell-intrinsic innate immune reaction against chromosomally unstable cells.
Alternatively, CIN might generate tumour-specific neoantigens, which are targeted by activated T cells in response to immune-checkpoint inhibition 129 or during adoptive T-cell therapy 130 . The effectiveness of immune-checkpoint inhibition is associated with having a high mutational burden of non-synonymous single-nucleotide variants (nsSNVs, which cause single amino acid substitutions), as reported in patients with melanoma, NSCLC, or cancers with DNA-mismatchrepair deficiencies 131 . As discussed earlier, cells with CIN are prone to accumulating mutations, but this is unlikely to substantially increase the number of nsSNVs. Genomic rearrangements associated with CIN, however, especially chromothripsis and chromoplexy 132 , have the potential to generate multiple frameshifts as a consequence of a single catastrophic event. By analyzing tumour mutational spectra in a pan-cancer study, Rare stochastic chromosome segregation errors are likely to be outcompeted but could persist. b | CIN occurring in the presence of functional stress response pathways, including activation of p53, will prevent the propagation of cells with complex karyotypes. Only aneuploidies involving specific chromosomes are likely to be tolerated, and cells will proliferate at a much slower rate. c | CIN tolerance enables rare stochastic errors from an otherwise karyotypically stable population to be efficiently propagated. Additional numerical and structural aberrations can then be acquired and propagated. d | High levels of CIN, despite mutations conferring CIN tolerance, will generate an increasing number of cells with unviable karyotypes and are therefore considered tumour suppressive. e | Alterations leading to a transient or less penetrant CIN phenotype will reduce the frequency of unviable karyotypes. Cells with CIN might also acquire secondary mutations that reduce both the incidence and severity of chromosome segregation errors, thus improving cellular fitness. S-CIN, structurally aberrant CIN; SCNAs, somatic copy-number alterations; W-CIN, whole-chromosome CIN.
we found that frameshift mutations might be a strong trigger of antitumour T cell reactivity 133 . Frameshifts result in the expression of aberrant neopeptides of various lengths that, upon processing by antigen-presenting cells, can potentially generate a much larger number of neoantigens than point mutations can. This observation might explain why clear cell renal cell carcinomas, which have a low nsSNV burden but a high frameshift burden, respond to immune-checkpoint inhibition 133 . Hence, the contribution of complex rearrangements as a source of neopeptides and their effects on the effectiveness of immune-checkpoint inhibition should be further explored.
Alternatively, ongoing CIN during immunecheckpoint inhibition might also lead to treatment failure. Indeed, acquired resistance to immune-checkpoint inhibitors in NSCLC has been linked with the loss of reactive cancer neoantigens owing to loss of heterozygosity 134 . This loss of neoantigens might be expected because CIN underpins the frequent loss of clonal mutations during the evolution of NSCLC 65 .
Further studies are needed to understand the global relevance of CIN for immunosurveillance, which should consider the metabolic stresses associated with aneuploidy, the immunogenicity associated with chromosome segregation errors, and the effect of CIN on neoantigen generation and elimination. Induction of CIN before immune-checkpoint inhibition might improve response rates; however, mitigating against continued CIN during treatment might be crucial to the avoidance of acquired resistance.
Leveraging CIN for cancer treatment Challenges in identifying CIN biomarkers. The current lack of biomarkers that enable the dynamic nature of the CIN phenotype to be captured, as opposed to the use of static indicators of aneuploidy and CNAs, is a major limitation of our ability to specifically leverage CIN for prognostic and therapeutic purposes. Assessments of DNA ploidy by use of image-based cytometry or flow cytometry enable the efficient detection of severe aneuploidies and/or tetraploidy, provide an indication of heterogeneity among tumour cells, and are useful methods of determining absolute copy number from sequencing data 135 . However, these methods lack reso lution and often fail to detect S-CIN or low levels of W-CIN, especially in near-diploid samples. Nuclear morphological defects in mitotic cells and micronuclei provide a surrogate indication of chromosome segre gation errors. Cytogenetic methods, which rely largely on analysis of cells during metaphase, cannot be applied in the clinical setting, and FISH-based methods can detect specific trans locations or measure centromeric modal deviation in only a limited number of chromosomes at once 136 . Both copy-number analysis using comparative genomic hybridization and sequencing of DNA from bulk tumour samples essentially reveal clonally selected alterations within any given tumour region and fail to detect the extent of cellular heterogeneity. This limitation is illustrated by the illusion of diploidy observed when analyzing highly aneuploid cellular populations or after mixing defined aneuploid clones 64, 137 . All of these methods provide information on the genomic complexity of cancer genomes but not on whether or not CIN is ongoing, or whether the errors are tolerated and/or propagated.
Multiregion sequencing can provide further insight into CIN dynamics, enabling investigators to distinguish between clonal and subclonal SCNAs, with a high proportion of subclonal SCNAs most likely indicative of ongoing CIN during tumour evolution. In patients with NSCLC, those with tumours in which the majority of SCNA events were subclonal had shorter disease-free survival durations; this effect was found to be independent of other clinical factors (including tumour stage) in multivariate analysis 65 . By contrast, a high proportion of subclonal mutations, indicating ongoing mutagenesis, had no prognostic value 65 . CIN might, therefore, be a more important driver of cancer progression than an increased mutation rate -a provocative thought that warrants further investigation.
Analysis of CTCs or cell-free tumour-derived DNA from liquid biopsy samples offers an amenable method of tracking SCNA evolution during cancer progression and treatment 66, [138] [139] [140] . In particular, low-coverage sequencing of genetic material from CTCs provides a non-invasive method of assessing tumour heterogeneity at the single-cell level to infer CIN 66 . Obviously, single-cell genomics provides the ultimate level of reso lution, enabling a full appreciation of the extent of hetero geneity, and represents the most promising avenue for the development of clinically applicable biomarkers of CIN 141 . Combining DNA image cytometry and multiregion sequencing could drive the identification of robust biomarkers capable of capturing the full extent of CIN dynamics, particularly in samples with a low tumour-cell fraction, which is crucial if we are to leverage CIN for patient stratification purposes or for direct therapeutic intervention.
CIN in clinical trials.
Considering the pervasiveness of CIN in cancer and the consequences of tumour hetero geneity for the effectiveness of cancer treatment, a very limited number of clinical trials (reported on clinicaltrials.gov) have been initiated to either directly investigate the clinical relevance of CIN, explore ways to leverage CIN therapeutically, or monitor CIN during disease progression or therapy. One trial currently recruiting participants (NCT03096418) is designed to directly investigate whether paclitaxel increases the levels of CIN in breast tumours, as suggested in initial studies 115 , and whether or not breast cancers with CIN are more sensitive to further instability resulting from neoadjuvant therapy. In this study, the level of aneuploidy and CIN will be measured using parallel methods including whole-genome sequencing and FISH on independent core samples from biopsies. In addition, the magnitude of patients' clinical responses will also be correlated with tumour levels of paclitaxel (measured using high-performance liquid chroma tography), as well as with those of biomarkers of proliferation (proliferation marker protein Ki67) and mitosis (phosphorylated histone H3). A trial completed in 2017 (NCT00512642) used lung imaging fluorescence endoscopy for the early detection of lung lesions in patients with a high risk of NSCLC. This trial involved the analysis of p53 status and the presence of genomic instability (aneuploidy) when lesions were found. The role of CIN in pre-malignant disease states and/or early stage disease could be further explored in patients with specific cancer types, as is planned for a study that is currently recruiting patients and is designed to investigate the correlation between ploidy and recurrence in patients with early stage rectal cancer (NCT03039595). Another interesting line of investigation deemed worthy of further exploration is to examine the occurrence of CIN in resection margins as a predictor of relapse, similar to what has been done in a study involving patients with oral squamous cell cancer 142 . In this study, 11 of 42 patients had local recurrence within 5 years of surgery, 9 of these 11 patients had tumour cells with CIN in at least one of the resection margins.
Perspectives on targeting CIN in patients with cancer. Given the far-reaching consequences of CIN for treatment success and patient outcomes, several approaches have been explored that might target CIN, taking advantage of features associated with the aneuploid state or the capacity of aneuploid cells to sustain further instability. Reducing the fitness of aneuploid cells can be achieved using compounds that exacerbate the proteotoxic stress (such as the heat shock protein 90 (HSP90) inhibitor 17-AAG) and metabolic stress (such as the AMPK agonist 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR)) associated with aneuploidy, methods which have shown some selectivity against cells with aneuploidy and CIN 87, 143 . Aneuploid and CIN-harbouring cell lines were found to contain higher levels of ceramides, a class of pro-apoptotic sphingolipids synthesized in the ER 144 , and consequently were demonstrated to be more sensitive to pharmacological increases in ceramide levels 145 . This observation might explain the reported synergy between conditions that increase ceramide levels and paclitaxel, which induces aberrant chromosome segregation at clinically relevant doses 115, [145] [146] [147] . Increasing the frequency of aberrant chromosome segregation in order to generate unviable karyotypes is another therapeutic avenue currently under active exploration. Several groups have developed MPS1 inhibitors aimed at causing massive aneuploidy by ablating the mitotic checkpoint, a mechanism that seems to synergize with the effects of paclitaxel 113, 125, 148 . Identifying cancer types that are exquisitely sensitive to MPS1 inhibitors might prove challenging and relies on the premise that unwanted aneuploidy in nonmalignant tissues is not propagated. The effectiveness of MPS1 inhibitors might, therefore, be restricted to the treatment of cancers in which paclitaxel has already been proven to be effective. The success of MPS1 inhibitor monotherapy might also be limited by the rapid acquisition of resistance, as observed in vitro, through MPS1 mutations, APC/C dysfunction, and acquisition of aneuploidy tolerance 95, 96, 149 . Forcing cells with additional centrosomes (such as those that have undergone genome doubling) into a catastrophic multipolar division, by preventing centrosome clustering, is also being explored, for example, by targeting the kinesin-like protein KIFC1 (REFS 15, 16, 150) . By accelerating mitosis, MPS1 inhibitors also impair centrosome clustering processes and promote the development of multipolarity 16, 95, 118 . Phase I studies exploring the safety and tolerability of MPS1 inhibitors (NCT02366949, NCT02138812, NCT02792465) are currently ongoing.
Targeting CIN-tolerance mechanisms, in combination with approaches aimed at increasing rates of CIN, might be an efficient method of limiting the acquisition of resistance and possibly might also improve responses to other therapies that incidentally increase the level of CIN. Targeting pathways that converge on p53, either by reactivating p53 in CIN tumours, disrupting interactions between G1/S-specific cyclin D1 and p21, or blocking activation of signalling pathways that induce tolerance, seems particularly relevant in this regard. For example, low doses of PI3Kα inhibitors, which dampen the low-level pathway activation that takes place upon oncogenic activation of PIK3CA, might reduce CIN tolerance and tumour heterogeneity and limit the generation of drug-resistant clones.
The ability to reduce tumour heterogeneity by directly suppressing aberrant chromosome segregation might be confounded by the complexity of the CIN phenotype in established tumours, and CIN might only be temporarily reduced, as was reported upon targeting a CINdriving process by use of a compound that potentiates kinesin-like protein KIF2C activity 151 . Further studies are needed to understand the evolutionary trajectories of heterogeneous CIN populations in response to various treatments, which might enable new targetable dependencies to be uncovered. A deeper understanding of the biological processes affecting the fitness of cells with CIN combined with the ongoing cataloguing of mutations associated with subclonal expansion might also enable the identification of additional druggable targets. In addition, whether acute induction of extreme CIN will potentiate antitumour immune responses or drive the development of resistance to immune-checkpoint inhibition warrants further investigation.
The prognostic value of aneuploidy has been demonstrated for several indications, although deriving robust approaches that enable clinicians to assess whether or not ongoing CIN is taking place within a given near-diploid or aneuploid sample might be crucial for the efficient exploitation of CIN in the clinical setting. Indeed, aneuploid cancer cells are not invariably chromosomally unstable and can maintain a stable yet abnormal karyotype. Discriminating between CIN-positive and CIN-negative tumours regardless of the ploidy status will potentially inform on both the response to therapy and the risk of relapse.
Conclusions
The development of robust biomarkers enabling the full extent of CIN dynamics to be captured is crucial if we are to leverage the potential of CIN for patient stratification purposes and for exploiting this feature for direct therapeutic intervention. Tackling CIN is essential for the success of personalized medicine, a problem that is only just beginning to be understood from a therapeutic perspective. Considerable attention has been given to the extremely diverse causes of CIN, although CIN-tolerance mechanisms, which are currently ripe for therapeutic exploitation, are starting to emerge as being crucial determinants of its propagation.
